JP2016519061A - 免疫原性ペプチドコンジュゲート及びそれを用いた抗インフルエンザ治療用抗体応答の誘導方法 - Google Patents
免疫原性ペプチドコンジュゲート及びそれを用いた抗インフルエンザ治療用抗体応答の誘導方法 Download PDFInfo
- Publication number
- JP2016519061A JP2016519061A JP2016502011A JP2016502011A JP2016519061A JP 2016519061 A JP2016519061 A JP 2016519061A JP 2016502011 A JP2016502011 A JP 2016502011A JP 2016502011 A JP2016502011 A JP 2016502011A JP 2016519061 A JP2016519061 A JP 2016519061A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- influenza
- hemagglutinin
- fir
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000863 peptide conjugate Substances 0.000 title claims abstract description 81
- 230000002163 immunogen Effects 0.000 title claims abstract description 61
- 206010022000 influenza Diseases 0.000 title claims abstract description 61
- 230000005875 antibody response Effects 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 31
- 230000001939 inductive effect Effects 0.000 title claims description 6
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 87
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 87
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 87
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 87
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 66
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 42
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 42
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 32
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 19
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 18
- 230000004927 fusion Effects 0.000 claims abstract description 15
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims abstract description 14
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 230000000977 initiatory effect Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 119
- 125000005647 linker group Chemical group 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 208000037797 influenza A Diseases 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 17
- 101710146275 Hemagglutinin 2 Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 102220637010 Actin-like protein 7A_S10T_mutation Human genes 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 claims description 13
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- 208000037798 influenza B Diseases 0.000 claims description 7
- 102220234440 rs572685299 Human genes 0.000 claims description 7
- 241000700721 Hepatitis B virus Species 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 241000701822 Bovine papillomavirus Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 5
- 102200058937 rs45581936 Human genes 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 108010058846 Ovalbumin Proteins 0.000 claims description 4
- 101800001707 Spacer peptide Proteins 0.000 claims description 4
- 108060003552 hemocyanin Proteins 0.000 claims description 4
- 229940092253 ovalbumin Drugs 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 101710132601 Capsid protein Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 101710116435 Outer membrane protein Proteins 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000814 tetanus toxoid Drugs 0.000 claims description 3
- 230000034217 membrane fusion Effects 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 20
- 239000000562 conjugate Substances 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 17
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000021615 conjugation Effects 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 6
- -1 aromatic amino acids Chemical class 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 210000004779 membrane envelope Anatomy 0.000 description 5
- 150000003141 primary amines Chemical group 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NRFJZTXWLKPZAV-UHFFFAOYSA-N N-(2-oxo-3-thiolanyl)acetamide Chemical compound CC(=O)NC1CCSC1=O NRFJZTXWLKPZAV-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 229960004753 citiolone Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MFRZPLYKVDHOSN-UHFFFAOYSA-N 4-(2-isocyanoethyl)morpholine Chemical compound [C-]#[N+]CCN1CCOCC1 MFRZPLYKVDHOSN-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108700031454 Bovine papillomavirus L1 Proteins 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102220532750 SPARC-like protein 1_L8A_mutation Human genes 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102200027165 rs201383094 Human genes 0.000 description 1
- 102200076325 rs5658 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本願は、2013年3月14日に出願の米国特許出願第13/828988号の一部継続出願であり、この文献は参照により全て本明細書に援用される。
本願に関する生物学的配列情報は、本願と共に提出したファイル名「TU−271−5−SEQ.txt」(2013年3月14日に作成。ファイルサイズ29368バイト。参照により本明細書に援用される)のASCIIテキストファイルに含まれる。
配列番号1のFIRペプチドをN末端Cys連結残基を追加して合成し、即ち配列番号19のペプチドを生成し、次にSMCC法を用いてKLHとコンジュゲートした。簡単に説明すると、キャリアKLHタンパク質をまず、SMCCを1つ以上の一級アミン基(例えば、キャリアタンパク質のリジン残基上)と反応させることで活性化した。得られた活性化キャリアを次に過剰なSMCC及びその副産物から分離した。次に、システイン誘導化FIRペプチドを活性化KLHと反応させた。システインのスルフヒドリル(チオール)基がSMCC誘導体化キャリアタンパク質のマレイミド部分の二重結合を越えて加わって共有スルフィド結合を形成する。次に、得られたFIRペプチド−KLHコンジュゲートを単離した。
5匹のBalb/Cマウスに実施例1で調製したコンジュゲートを注射した。最初の注射は、0日目に完全フロインドアジュバントと混合したFIRペプチド−KLHコンジュゲートを利用した。21、35、49及び63日目に、マウスに、不完全フロインドアジュバント中のFIR−ペプチド−KLHコンジュゲートを注射した。血清サンプルをマウスから45、59及び73日目に採取し、96ウェルプラスチックプレートのウェルにFIRペプチド(配列番号1)が受動的に結合したELISA法を用いて抗FIRペプチド抗体の存在について試験した。高力価の抗FIR抗体を有する3匹のマウスを屠殺し、脾臓を回収した。標準的な技法を用いて、脾細胞を回収し、sp2/0細胞とを融合させ、抗FIR抗体を産生するハイブリドーマをELISAにより同定し、限界希釈によりサブクローニングした。幾つかのクローンが同定され、MAF3−2と称されるものをさらなる分析において使用した。
ヤギに実施例1で調製したコンジュゲートを注射した。1回目の注射は、完全フロインドアジュバント中の500μgのFIRペプチド−KLHコンジュゲートで行われた。続く注射(2週間間隔)は不完全フロインドアジュバント中の250μg用量のコンジュゲートで行われた。全部で3回の注射後、最初の注射から5週目に血清サンプルを用意した。プレートELISA試験において、血清サンプルがFIRペプチドに対して検出可能な力価を有すると判明した。
2羽のウサギに実施例1で調製したコンジュゲートを注射した。1回目の注射は、完全フロインドアジュバント中の200μgのFIRペプチド−KLHコンジュゲートで行われた。続く注射(2週間間隔)は不完全フロインドアジュバント中の100μg用量のコンジュゲートで行われた。全部で3回の注射後、最初の注射から5週目に血清サンプルを各ウサギから採取した。プレートELISA試験において、血清サンプルがFIRペプチドに対して検出可能な力価を有すると判明した。
実施例2のFIRペプチドに対する単離されたマウス由来モノクローナル抗体(MAF3−2)は、FIRペプチド抗原との競合により一般に定義されるようにヘマグルチニン(HA)の様々なサブタイプを認識し、特異的に結合すると判明した。特異性を実証するために、96ウェルイムノアッセイプレートのウェルに、カーボネート/バイカーボネートバッファに溶解させた様々なサブタイプの市販のヘマグルチニン(HA:H1株A/カリフォルニア/04/2009(H1N1)pdm09;H3株A/ウルグアイ/716/07(H3N2);H3株A/ウィスコンシン/67/2005(H3N2);H5株A/インドガン/青海/1A/05(H5N1))をコーティングした。プラスチック上の非結合荷電部位は緩衝脱脂粉乳/洗浄剤懸濁液でブロックされた。精製されたMAF3−2抗体をビオチンにカップリングした(btn−MAF3−2)。次に、抗体溶液の約0.1mLのアリコートを、HAコーティングプレートに加える前の約45分間にわたってFIRペプチドの段階希釈により中和した。さらなるインキュベーション後、ウェルを緩衝生理食塩水含有洗浄剤で洗浄した。結合したFIR抗体は、ストレプトアビジン−西洋ワサビペルオキシダーゼコンジュゲートとのインキュベーションと続く洗浄及び比色試薬である3,3’,5,5’−テトラメチルベンジジンの適用により検出された。図3は、ELISAプレート結合HAと遊離FIRペプチドとの間での結合競合のグラフであり、抗FIRペプチド抗体のFIR抗原に対する特異性をここでも実証している。
細胞及びウイルス:メイディン・ダービー・イヌ腎臓細胞(MDCK)を全ての実験に使用した。細胞を、ペニシリン/ストレプトマイシン溶液、炭酸水素ナトリウム溶液、非必須アミノ酸溶液及び熱失活ウシ胎仔血清を補充した完全ダルベッコ最小必須培地(cDMEM)で維持し、増殖させた。表2に含まれるインフルエンザウイルスを全ての感染/抗体結合研究に使用した。全てのウイルスを標準的な方法を用いて生後9日の発育鶏卵で増殖させ、尿膜液からの遠心分離により精製した。全ての感染を、5.0の感染多重度で行った。
Claims (20)
- キャリアタンパク質に連結基でコンジュゲートされたヘマグルチニン(HA)融合開始領域(FIR)ペプチド又はその変異体を含む免疫原性ペプチドコンジュゲートであって、前記HA FIRペプチドが、50個以下のアミノ酸残基から成り、また配列番号1又は少なくとも50%の配列同一性を共有し且つ配列番号1とは、V1I、V1L、V1A、V1G、V1T、V1S、V1M、E2D、E2K、E2R、D3E、T4G、T4S、T4Q、T4A、K5F、K5M、K5I、K5V、K5L、K5A、I6L、I6V、I6A、I6T、I6S、I6Q、I6N、D7E、L8I、L8V、L8A、W9Y、S10T、S10G、S10A、S10M及びE14Kから成る群から選択される1つ以上のアミノ酸置換で異なる配列番号1の変異体のアミノ酸配列を含むインフルエンザヘマグルチニン2タンパク質のセグメントを含むことを特徴とする、免疫原性ペプチドコンジュゲート。
- 前記インフルエンザヘマグルチニン2タンパク質のセグメントは、H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、H16及びH17から成る群から選択されるインフルエンザAサブタイプのヘマグルチニン2タンパク質からの25個までの追加のアミノ酸残基を含み、前記追加の残基が、配列番号1又はその変異体に、選択したインフルエンザAサブタイプのヘマグルチニン2タンパク質のアミノ酸配列において隣接している、請求項1に記載の免疫原性ペプチドコンジュゲート。
- 前記HA FIRペプチドが、インフルエンザAヘマグルチニン2タンパク質由来ではない1つ以上のペプチド配列を含む、請求項1又は2に記載の免疫原性ペプチドコンジュゲート。
- 前記ヘマグルチニンFIRペプチドが、配列番号1又は少なくとも50%の配列同一性を共有し且つ配列番号1とはV1I、V1L、V1A、V1G、V1T、V1S、V1M、E2D、E2K、E2R、D3E、T4G、T4S、T4Q、T4A、K5F、K5M、K5I、K5V、K5L、K5A、I6L、I6V、I6A、I6T、I6S、I6Q、I6N、D7E、L8I、L8V、L8A、W9Y、S10T、S10G、S10A、S10M及びE14Kから成る群から選択される1つ以上のアミノ酸置換で異なる配列番号1の変異体から成るアミノ酸配列を有する、請求項1〜3のいずれかに記載の免疫原性ペプチドコンジュゲート。
- 前記キャリアタンパク質が、髄膜炎菌の外膜タンパク質複合体(OMPC)、破傷風トキソイドタンパク質、ジフテリア毒素誘導体CRM197、ウシ血清アルブミン(BSA)、カチオン化BSA、コンコレパス・コンコレパスヘモシアニン(CCH)、B型肝炎ウイルス(HBV)表面抗原タンパク質(HBsAg)、HBVコア抗原タンパク質、キーホール・リンペットヘモシアニン(KLH)、ロタウイルスカプシドタンパク質、ウシパピローマウイルス(BPV)L1タンパク質、ヒトパピローマウイルス(HPV)L1タンパク質、オボアルブミン及び全長インフルエンザヘマグルチニンタンパク質から成る群から選択される、請求項1〜4のいずれかに記載の免疫原性ペプチドコンジュゲート。
- 前記キャリアタンパク質は全長インフルエンザヘマグルチニンタンパク質である、請求項1〜5のいずれかに記載の免疫原性ペプチドコンジュゲート。
- 前記全長インフルエンザヘマグルチニンタンパク質が、H1、H2、H3、H4、H5、H6、H7、H8、H9、H10、H11、H12、H13、H14、H15、H16及びH17から成る群から選択されるインフルエンザAサブタイプ由来のヘマグルチニンである、請求項6に記載の免疫原性ペプチドコンジュゲート。
- 前記全長インフルエンザヘマグルチニンタンパク質が、インフルエンザBヘマグルチニンタンパク質である、請求項6に記載の免疫原性ペプチドコンジュゲート。
- 前記連結基が、スルフィド結合を含む、請求項1〜8のいずれかに記載の免疫原性ペプチドコンジュゲート。
- 前記連結基が、実施形態1〜6のいずれかに記載のペプチドコンジュゲートを含み、前記連結基が、式I、
- 前記連結基により前記キャリアタンパク質にコンジュゲートされた配列番号1から成るアミノ酸配列を有するヘマグルチニン2FIRペプチドを含む、請求項1〜10のいずれかに記載の免疫原性ペプチドコンジュゲート。
- 請求項1〜11のいずれかに記載の免疫原性ペプチドコンジュゲートを医薬的に許容可能なキャリア中に含む、インフルエンザ感染症を治療又は予防するための医薬組成物。
- 治療有効量の請求項1〜11のいずれかに記載の免疫原性ペプチドコンジュゲートをインフルエンザに罹患している又はインフルエンザに罹る恐れがある被験者に投与することを含む、インフルエンザ感染症を治療又は予防するための方法。
- 請求項1〜11のいずれかに記載の免疫原性ペプチドコンジュゲートを被験者に投与することを含む、インフルエンザウイルスに対する特異的治療用抗体応答を被験者において誘導する方法。
- 前記特異的治療用抗体応答はインフルエンザウイルスと宿主細胞の膜との融合を阻害する、請求項14に記載の方法。
- 請求項1〜11のいずれかに記載の免疫原性ペプチドコンジュゲートの投与後に宿主生物内で産生された抗体からの相補性決定領域(CDR)を含み、インフルエンザウイルスヘマグルチニンタンパク質のFIR領域に特異的に結合する、インフルエンザウイルスヘマグルチニンタンパク質のFIR領域に特異的に結合可能な治療用モノクローナル抗体。
- ヒト、ヒト化又はキメラモノクローナル抗体である、請求項16に記載の治療用モノクローナル抗体。
- インフルエンザ感染症を治療又は予防するための請求項16又は17に記載の治療用モノクローナル抗体の使用。
- インフルエンザ感染症を治療又は予防するための請求項1〜11のいずれかに記載の免疫原性ペプチドコンジュゲートの使用。
- 被験者においてインフルエンザウイルスに対する特異的治療用抗体応答を誘導するための請求項1〜11のいずれかに記載の免疫原性ペプチドコンジュゲートの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/828,988 | 2013-03-14 | ||
US13/828,988 US9649375B2 (en) | 2013-03-14 | 2013-03-14 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
PCT/US2014/025968 WO2014160171A2 (en) | 2013-03-14 | 2014-03-13 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016519061A true JP2016519061A (ja) | 2016-06-30 |
JP2016519061A5 JP2016519061A5 (ja) | 2017-04-13 |
Family
ID=51527967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016502011A Pending JP2016519061A (ja) | 2013-03-14 | 2014-03-13 | 免疫原性ペプチドコンジュゲート及びそれを用いた抗インフルエンザ治療用抗体応答の誘導方法 |
Country Status (12)
Country | Link |
---|---|
US (3) | US9649375B2 (ja) |
EP (1) | EP2970386A4 (ja) |
JP (1) | JP2016519061A (ja) |
CN (1) | CN105377876A (ja) |
AR (1) | AR095367A1 (ja) |
AU (2) | AU2014244071B2 (ja) |
CA (1) | CA2906519A1 (ja) |
EA (1) | EA030004B1 (ja) |
HK (1) | HK1222184A1 (ja) |
MX (1) | MX2015012399A (ja) |
TW (2) | TWI654205B (ja) |
WO (1) | WO2014160171A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018129624A1 (en) * | 2017-01-13 | 2018-07-19 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
WO2018237010A2 (en) | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE |
CN114516907B (zh) * | 2020-11-20 | 2024-03-29 | 中国科学技术大学 | 一种植物抗逆性相关基因atagl70及其编码蛋白与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007514408A (ja) * | 2003-11-04 | 2007-06-07 | ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | クラスi膜融合誘発性エンベロープタンパク質をもつrnaウイルスの融合開始領域の機能を阻害することによってウイルス:細胞融合を妨げる方法 |
JP2010531362A (ja) * | 2007-06-25 | 2010-09-24 | ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド | インフルエンザを阻害する組成物および方法 |
WO2010124373A1 (en) * | 2009-04-29 | 2010-11-04 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Influenza vaccine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98845A0 (en) | 1990-07-19 | 1992-07-15 | Merck & Co Inc | Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
US7479285B1 (en) * | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
WO2003105782A2 (en) | 2002-06-17 | 2003-12-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
SG2014012868A (en) * | 2005-10-18 | 2014-09-26 | Novavax Inc | Functional influenza virus like particles (vlps) |
WO2007051036A2 (en) | 2005-10-26 | 2007-05-03 | Protelix, Inc. | Influenza combinatorial antigen vaccine |
US8222204B2 (en) * | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
BRPI0711229A2 (pt) | 2006-05-31 | 2013-01-08 | Astellas Pharma Inc | anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana |
EP2265646B1 (en) * | 2008-03-12 | 2016-01-27 | Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health | Reagents and methods for detecting influenza virus proteins |
CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
WO2010124393A1 (en) | 2009-04-30 | 2010-11-04 | National Research Council Of Canada | Anticancer agent comprising a yatapoxvirus mutant and uses thereof |
BRPI1012749B1 (pt) | 2009-05-11 | 2022-01-11 | Janssen Vaccines & Prevention B.V. | Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica |
EP2528622A2 (en) * | 2010-01-26 | 2012-12-05 | The Regents of the University of Colorado | Influenza virus epitopes templated into double-stranded coiled coils and use thereof in immunization |
MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
-
2013
- 2013-03-14 US US13/828,988 patent/US9649375B2/en active Active
-
2014
- 2014-03-12 AR ARP140100906A patent/AR095367A1/es unknown
- 2014-03-13 CA CA2906519A patent/CA2906519A1/en not_active Abandoned
- 2014-03-13 WO PCT/US2014/025968 patent/WO2014160171A2/en active Application Filing
- 2014-03-13 EA EA201591747A patent/EA030004B1/ru not_active IP Right Cessation
- 2014-03-13 TW TW103109171A patent/TWI654205B/zh not_active IP Right Cessation
- 2014-03-13 JP JP2016502011A patent/JP2016519061A/ja active Pending
- 2014-03-13 TW TW107137751A patent/TW201925238A/zh unknown
- 2014-03-13 CN CN201480028403.5A patent/CN105377876A/zh active Pending
- 2014-03-13 MX MX2015012399A patent/MX2015012399A/es unknown
- 2014-03-13 AU AU2014244071A patent/AU2014244071B2/en not_active Ceased
- 2014-03-13 EP EP14776544.0A patent/EP2970386A4/en not_active Withdrawn
-
2016
- 2016-08-31 HK HK16110325.7A patent/HK1222184A1/zh unknown
-
2017
- 2017-05-10 US US15/591,386 patent/US10137194B2/en active Active - Reinstated
-
2018
- 2018-10-04 AU AU2018241125A patent/AU2018241125A1/en not_active Abandoned
- 2018-10-31 US US16/176,743 patent/US10537634B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007514408A (ja) * | 2003-11-04 | 2007-06-07 | ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | クラスi膜融合誘発性エンベロープタンパク質をもつrnaウイルスの融合開始領域の機能を阻害することによってウイルス:細胞融合を妨げる方法 |
JP2010531362A (ja) * | 2007-06-25 | 2010-09-24 | ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド | インフルエンザを阻害する組成物および方法 |
WO2010124373A1 (en) * | 2009-04-29 | 2010-11-04 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Influenza vaccine |
Non-Patent Citations (1)
Title |
---|
CURR. PROTOC. NEUROSCI., 2001, CHAPTER 5, UNIT 5.6, JPN6019001523 * |
Also Published As
Publication number | Publication date |
---|---|
EA201591747A1 (ru) | 2016-02-29 |
CA2906519A1 (en) | 2014-10-02 |
CN105377876A (zh) | 2016-03-02 |
US9649375B2 (en) | 2017-05-16 |
EP2970386A2 (en) | 2016-01-20 |
US20140271650A1 (en) | 2014-09-18 |
EP2970386A4 (en) | 2016-10-26 |
MX2015012399A (es) | 2016-03-03 |
AU2014244071A1 (en) | 2015-10-29 |
US20170258902A1 (en) | 2017-09-14 |
US10537634B2 (en) | 2020-01-21 |
TW201925238A (zh) | 2019-07-01 |
TWI654205B (zh) | 2019-03-21 |
US10137194B2 (en) | 2018-11-27 |
HK1222184A1 (zh) | 2017-06-23 |
TW201514208A (zh) | 2015-04-16 |
WO2014160171A2 (en) | 2014-10-02 |
AR095367A1 (es) | 2015-10-14 |
AU2018241125A1 (en) | 2018-10-25 |
EA030004B1 (ru) | 2018-06-29 |
WO2014160171A3 (en) | 2015-04-23 |
US20190054168A1 (en) | 2019-02-21 |
AU2014244071B2 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11969466B2 (en) | Stabilized influenza hemagglutinin stem region trimers and uses thereof | |
US10137190B2 (en) | Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins | |
US20220288189A1 (en) | Influenza hemagglutinin proteins and methods of use thereof | |
US20220072120A1 (en) | Nanoparticle-based influenza virus vaccines and uses thereof | |
US20040223976A1 (en) | Influenza virus vaccine | |
KR20010081068A (ko) | 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 hbv 코어 항원 입자 | |
TW201329101A (zh) | 流感病毒疫苗及其用途 | |
US10537634B2 (en) | Immunogenic peptide composition and method | |
WO2023220614A2 (en) | Recombinant subunit based universal influenza and respiratory virus vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170310 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180824 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190124 |